OSI-906 (Linsitinib) 化学構造
分子量: 421.49

高品質保証

カスタマーフィードバック(3)

Quality Control & MSDS

製品説明

  • Compare IGF-1R Inhibitors
    IGF-1R製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 OSI-906(Linsitinib)は、IGF-IRとIrの選択的な阻害剤で、IC50 がそれぞれ 35 nM と 75 nMです。
ターゲット IGF-1R InsR
IC50 35 nM 75 nM [1]
In vitro試験 OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
A4-Fuk NU\5cG5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3hS212UUN3ME2wMlAzQDB4IN88US=> NFm2UWhUSU6JRWK=
KS-1 MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu2dIlKSzVyPUCuNFM5OzVizszN NIftVFhUSU6JRWK=
TE-11 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TI[WlEPTB;MD6wO|gzOiEQvF2= M4H1cHNCVkeHUh?=
EW-1 MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfTO25KSzVyPUCuNFg2QDVizszN MnLWV2FPT0WU
HMV-II NEnJdI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzjTWM2OD1yLkC4PFQ3KM7:TR?= M2rTUnNCVkeHUh?=
COLO-205 M3;JOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\pcGlEPTB;MD6xNFQ2PCEQvF2= MkDkV2FPT0WU
ES1 M1e5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMUC2PVYh|ryP Ml3QV2FPT0WU
GDM-1 MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXrRllKSzVyPUCuNVM3PzJizszN NFvq[HVUSU6JRWK=
ML-2 M1fISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMUW4PVYh|ryP MlnuV2FPT0WU
Saos-2 M2LxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMU[1NlYh|ryP MYrTRW5ITVJ?
NCI-H1355 M3v2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljkTWM2OD1yLkG4NVM2KM7:TR?= NUOwXFNjW0GQR1XS
G-401 M2O2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMUiyN{DPxE1? MXTTRW5ITVJ?
EW-16 NFvpNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[3ZVNGUUN3ME2wMlE5Pzd5IN88US=> MnnNV2FPT0WU
EW-7 NF;HT3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTyZ3NiUUN3ME2wMlE5QDhzIN88US=> M4fnTXNCVkeHUh?=
NCI-H727 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rLVGlEPTB;MD6xPVc6PCEQvF2= NE\xU|BUSU6JRWK=
LCLC-97TM1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnXPIpKSzVyPUCuNlA6PTVizszN NFHEbWNUSU6JRWK=
NCI-H650 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwMkGzPFQh|ryP NGPWTZNUSU6JRWK=
NCI-H2122 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEexelRKSzVyPUCuNlMzQTlizszN MkS2V2FPT0WU
SK-N-DZ M2LYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HrVmlEPTB;MD6yN|Y6QCEQvF2= NV7henA3W0GQR1XS
HT-29 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkn2TWM2OD1yLkK0NlQ5KM7:TR?= NX\pPWljW0GQR1XS
LB771-HNC NYHDO2x1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTROWJKSzVyPUCuNlU6OTVizszN MnWxV2FPT0WU
HT-144 M4j4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrETWM2OD1yLkK2NVkyKM7:TR?= MkPTV2FPT0WU
LAN-6 MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXPeoZvUUN3ME2wMlI3OzR6IN88US=> NULaO2JXW0GQR1XS
EW-18 M{jhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLmTWM2OD1yLkK3NFAyKM7:TR?= NHSxdppUSU6JRWK=
LS-1034 M1Hmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMkexN|Ih|ryP NVvFOYhZW0GQR1XS
EW-11 MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnzfHJRUUN3ME2wMlI5PDN{IN88US=> NEnB[5dUSU6JRWK=
SNU-C1 NXTkUoY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnPTWM2OD1yLkK5N|E{KM7:TR?= MVTTRW5ITVJ?
RS4-11 NY\I[HJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;LUWRvUUN3ME2wMlM{PzV6IN88US=> MnTNV2FPT0WU
ES4 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HCR2lEPTB;MD60NVA{QCEQvF2= M2PXcXNCVkeHUh?=
COLO-320-HSR M2nuV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwNEGzOlgh|ryP M4PoVnNCVkeHUh?=
NB10 NETvU4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvhTWM2OD1yLkS1OFM4KM7:TR?= M{jpO3NCVkeHUh?=
BFTC-905 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoqyTWM2OD1yLkS2O|U5KM7:TR?= M3fkSnNCVkeHUh?=
A375 NHyxNW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[1SGlEPTB;MD60O|YyPyEQvF2= NHuxUJlUSU6JRWK=
SJRH30 NFuwb3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwNUC4NlIh|ryP NGO3OG1USU6JRWK=
NOS-1 NGKwVo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;WemFpUUN3ME2wMlUzOjZ5IN88US=> NUPJOlJLW0GQR1XS
SIG-M5 NX3afmNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwNUO1OVch|ryP Mof1V2FPT0WU
DOK Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnOyTWM2OD1yLkW1OkDPxE1? MYfTRW5ITVJ?
NB69 NFPWem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHVTWM2OD1yLkW4NlU4KM7:TR?= M2HQRXNCVkeHUh?=
SK-NEP-1 NHOwVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHLNIZKSzVyPUCuOlAzOzZizszN MX7TRW5ITVJ?
SK-MM-2 M1L3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEixPXVKSzVyPUCuOlU1QTFizszN NUHl[2ZWW0GQR1XS
NCI-H358 MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrUZYRHUUN3ME2wMlY4ODh{IN88US=> NV[1WFRjW0GQR1XS
RH-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jFR2lEPTB;MD63OFg2QSEQvF2= MVPTRW5ITVJ?
NH-12 NE\CNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwN{[wOFYh|ryP MlLHV2FPT0WU
TE-12 NFr2TYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:wU2lEPTB;MD63OlQ5PiEQvF2= MVvTRW5ITVJ?
COLO-668 M2C2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XJd2lEPTB;MD64OFY3PiEQvF2= NXnUVm53W0GQR1XS
PANC-08-13 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlryTWM2OD1yLki2N|c4KM7:TR?= MXvTRW5ITVJ?
HCC2998 NFGweYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwOEiyOlMh|ryP NGnwbmRUSU6JRWK=
ABC-1 NGHTfFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknNTWM2OD1yLkmwN|UzKM7:TR?= M1\5PHNCVkeHUh?=
ES6 NGjC[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfI[4R5UUN3ME2wMlkyODZ4IN88US=> Ml[2V2FPT0WU
SNU-387 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX6ZmVKSzVyPUCuPVk{QTNizszN NH;yPXVUSU6JRWK=
CMK M2fObGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwOUm5Nlkh|ryP M2T1fXNCVkeHUh?=
SJSA-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHaNpJKSzVyPUGuNFM3PTNizszN NETTR|hUSU6JRWK=
SIMA NUm3eVR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTFwME[4NlUh|ryP NIDRUFVUSU6JRWK=
ES3 NHfwWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7qdlY5UUN3ME2xMlEzOjl5IN88US=> MkTQV2FPT0WU
IGROV-1 M1LuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTFwMUW0OFQh|ryP NWrLd2xiW0GQR1XS
MEL-JUSO M1zYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTFwMUW3OVkh|ryP NWTvNG5sW0GQR1XS
T84 NX7ZSHlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XmdGlEPTB;MT6yNFkyPCEQvF2= MXzTRW5ITVJ?
CAL-85-1 M2noeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvHWHFKSzVyPUGuNlMyOzhizszN MWnTRW5ITVJ?
RD NIWyTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\Bb2x4UUN3ME2xMlI3PDV3IN88US=> NFjRemRUSU6JRWK=
TE-8 MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVr3doQ1UUN3ME2xMlMyPDZ{IN88US=> M{DEenNCVkeHUh?=
L-363 M2ezfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4OyRWlEPTB;MT6zOFIxQCEQvF2= MnLjV2FPT0WU
EKVX NFO4cHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvEXHZMUUN3ME2xMlM1PTZ6IN88US=> MXfTRW5ITVJ?
SK-MEL-3 NHjZNVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFy1R5JKSzVyPUGuOFg2PTZizszN NWr2OIY3W0GQR1XS
TGBC24TKB M1ryOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ntXWlEPTB;MT61NFE6OyEQvF2= MmLvV2FPT0WU
NCI-H1770 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHFTWM2OD1zLkWxNVE{KM7:TR?= MlraV2FPT0WU
HuH-7 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jteWlEPTB;MT62NFA6QCEQvF2= NWPHZ5FJW0GQR1XS
HL-60 NXn1NYc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1exU2lEPTB;MT62OlkzQCEQvF2= MV\TRW5ITVJ?
TE-1 NGXjeG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;hVGlEPTB;MT63NFk1PSEQvF2= MVnTRW5ITVJ?
LC-2-ad NXL4bmNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoH4TWM2OD1zLkezPFg4KM7:TR?= MmPKV2FPT0WU
LB647-SCLC MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFwN{[1PFMh|ryP NILrVGJUSU6JRWK=
NCI-H2171 MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;teWlEPTB;MT63O|cyPiEQvF2= NEXweGRUSU6JRWK=
SK-PN-DW MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFwOUGyPVgh|ryP NXniTlNzW0GQR1XS
MC-IXC M2XnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HYSGlEPTB;MT65PFk5KM7:TR?= NYG1[XZqW0GQR1XS
LS-513 MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorGTWM2OD1{LkC1N|A2KM7:TR?= MVHTRW5ITVJ?
EW-3 MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJwMEm4OFQh|ryP M1H5d3NCVkeHUh?=
OPM-2 NEmwOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJwMUCyJO69VQ>? NIrjSJZUSU6JRWK=
LP-1 MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17WZmlEPTB;Mj6yOVgxPyEQvF2= NXjTb5o1W0GQR1XS
LU-134-A MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTyR3JVUUN3ME2yMlI4PyEQvF2= MX3TRW5ITVJ?
CP66-MEL M3vpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHvVnNKSzVyPUKuNlkxOTRizszN M333OHNCVkeHUh?=
HCC1143 MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXoR3FKSzVyPUKuOFU{PjhizszN MVTTRW5ITVJ?
LOXIMVI MkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHQOHVKSzVyPUKuOlAzOSEQvF2= NHv3XHlUSU6JRWK=
TE-10 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1uzc2lEPTB;Mj63NFg{QCEQvF2= NGXM[VdUSU6JRWK=
NCI-H1882 M2\xVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJwN{WyNlch|ryP NYL2R2ZXW0GQR1XS
CHP-126 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTJwN{[zNVch|ryP M2PLNXNCVkeHUh?=
NCI-H1623 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXqeW01UUN3ME2yMlkzODJ2IN88US=> M2LYR3NCVkeHUh?=
GB-1 NVjUeXRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDqTWM2OD1{LkmzOFA1KM7:TR?= M4PmT3NCVkeHUh?=
RCC10RGB M4m4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fNNWlEPTB;Mj65OVI5OSEQvF2= MV7TRW5ITVJ?
NCI-H2141 M2riXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjnVWZTUUN3ME2yMlk3QDl4IN88US=> Ml\2V2FPT0WU
GI-ME-N NHTZ[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjDT4EzUUN3ME2zMlAxPTZ3IN88US=> NFXC[lVUSU6JRWK=
NCI-H526 MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfiZ2k1UUN3ME2zMlA1ODh3IN88US=> MXXTRW5ITVJ?
NCI-H747 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXMRY5tUUN3ME2zMlA1QTl{IN88US=> NFLCXI5USU6JRWK=
SNU-423 NFHWO41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF74b3VKSzVyPUOuNlA{OTNizszN NXfCWFJnW0GQR1XS
A427 M4DqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;zTWM2OD1|LkK1Olk6KM7:TR?= NUXhfIVoW0GQR1XS
CAL-12T NUjS[G1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;wTWM2OD1|LkSwO|E{KM7:TR?= NGnVdJRUSU6JRWK=
LU-99A MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LCdGlEPTB;Mz60O|ExPSEQvF2= MVfTRW5ITVJ?
MS-1 M{\DfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHKbohKSzVyPUOuOVM1OjlizszN M1ewZnNCVkeHUh?=
SK-LU-1 MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4SxW2lEPTB;Mz63OlI6PSEQvF2= MUjTRW5ITVJ?
SW837 NWXiTlFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTNwN{[zN|Mh|ryP M33KbnNCVkeHUh?=
ES8 NWDUOIpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33RSmlEPTB;Mz64N|g4PyEQvF2= NVTEb|U4W0GQR1XS
MZ2-MEL NFrUclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HyTGlEPTB;Mz65NlA5PiEQvF2= MnHkV2FPT0WU
TGW NEnqe2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTRwMEGzNVEh|ryP M2TJdXNCVkeHUh?=
GP5d MnXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrjTWM2OD12LkC1N|YzKM7:TR?= NI\GXJdUSU6JRWK=
BB49-HNC M{PxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTRwMUWyNVMh|ryP NHfQSG1USU6JRWK=
NB13 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3jOpRKSzVyPUSuNlY5QDdizszN M2PsfnNCVkeHUh?=
NTERA-S-cl-D1 M{fkSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Hob2lEPTB;ND6yPFYyPSEQvF2= M1:xbHNCVkeHUh?=
NCI-H1648 M{DXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHtdlF4UUN3ME20MlI6QDF7IN88US=> MlTUV2FPT0WU
LCLC-103H M2\pPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTRwM{KxPVUh|ryP NX;mU3dLW0GQR1XS
LS-411N MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe2Vog4UUN3ME20MlQ1QDh3IN88US=> M3vBcHNCVkeHUh?=
NCI-H1092 NV;oNIIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGOxWoFKSzVyPUSuOFU3QDdizszN MYHTRW5ITVJ?
PANC-10-05 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PVUGlEPTB;ND62PVg1KM7:TR?= MY\TRW5ITVJ?
DK-MG NYnGUJVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHu0ZZhKSzVyPUSuPFA6OzNizszN M3PReHNCVkeHUh?=
OVCAR-5 NXvrUWx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUniXmE3UUN3ME20MlgyOjJ4IN88US=> NUfRR5I2W0GQR1XS
CAL-39 NFTUXHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTRwOEe2O{DPxE1? MW\TRW5ITVJ?
TE-441-T NFG2VG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXS3ZWJRUUN3ME20MlkxPTN5IN88US=> NV3ofXcxW0GQR1XS
MOLT-16 MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFH1fmNKSzVyPUSuPVUzPTNizszN MVjTRW5ITVJ?
MCF7 NVnJ[IxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfRTWM2OD13LkG0OVE4KM7:TR?= M{jnNnNCVkeHUh?=
CAPAN-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPqe|hTUUN3ME21MlI2PzB5IN88US=> MXHTRW5ITVJ?
PSN1 MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\QXXNiUUN3ME21MlI4OjN3IN88US=> NUPi[WVNW0GQR1XS
NCI-H292 M2rSTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYL0cGtsUUN3ME21MlMxODR2IN88US=> NEPwOlVUSU6JRWK=
CPC-N MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfCWlZ4UUN3ME21MlM6PDF7IN88US=> M4nhbHNCVkeHUh?=
DoTc2-4510 NHPLPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m5[mlEPTB;NT60OVM4OSEQvF2= M3:yOnNCVkeHUh?=
LB1047-RCC MlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXTTWM2OD13LkW1PVM{KM7:TR?= M2rYN3NCVkeHUh?=
MHH-ES-1 M{PkRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HUU2lEPTB;NT61PVkxPyEQvF2= MWPTRW5ITVJ?
NMC-G1 Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nUO2lEPTB;NT63NFIzPyEQvF2= M1Lo[nNCVkeHUh?=
SW1710 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TNZWlEPTB;NT63OFc2OSEQvF2= NGPBcWxUSU6JRWK=
YAPC MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTVwN{[yNFEh|ryP MnnFV2FPT0WU
22RV1 NEfMfWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\IXYh6UUN3ME21MlgxODF7IN88US=> NWnWclh{W0GQR1XS
COLO-679 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrOTWM2OD13Lki4PVQ5KM7:TR?= MnjjV2FPT0WU
TCCSUP MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzyTWM2OD13LkmzNlU6KM7:TR?= MkK4V2FPT0WU
C2BBe1 M1LyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnibpZKSzVyPUWuPVM6PyEQvF2= NXK4b5BCW0GQR1XS
TE-15 MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTZwME[2NFUh|ryP NI[yfW1USU6JRWK=
SCLC-21H NU\ESphuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPqR4Q1UUN3ME22MlExQDR|IN88US=> Mlr1V2FPT0WU
EoL-1-cell MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7tTWM2OD14LkG2OVY{KM7:TR?= NV;4TGl7W0GQR1XS
NKM-1 NVHsVWJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XOfmlEPTB;Nj6xOlcyKM7:TR?= NGO3enhUSU6JRWK=
NCI-H1304 M3XnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHsfllKSzVyPU[uNlc1OjhizszN NY\6d4dHW0GQR1XS
NB6 NH3QWWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nmTGlEPTB;Nj6yPVYzOiEQvF2= NYXSc4dbW0GQR1XS
NALM-6 NF7DUoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTZwM{OyN{DPxE1? NHn4c4ZUSU6JRWK=
NCI-H522 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXjUGNKSzVyPU[uN|M{ODZizszN NFrYTo1USU6JRWK=
MV-4-11 M2rYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3MS2dsUUN3ME22MlM4ODd7IN88US=> M3X6N3NCVkeHUh?=
LB2241-RCC M{HFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTZwM{i2Olch|ryP M2[xfHNCVkeHUh?=
NCI-H1417 NV\NeJA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTZwNEC4OFch|ryP M3r4RnNCVkeHUh?=
HT-1197 M{PJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHX5VHVKSzVyPU[uOVcyOjJizszN NVTtOo5ZW0GQR1XS
P30-OHK NWr6W|Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIOwc4RKSzVyPU[uOlI4PyEQvF2= MofWV2FPT0WU
ALL-PO MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\kTWM2OD14LkexPVE3KM7:TR?= MXnTRW5ITVJ?
OVCAR-4 M4qySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTZwN{W0NFUh|ryP MYnTRW5ITVJ?
HCC2157 M4S2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\C[ZBKSzVyPU[uO|c1PzVizszN M4DmPHNCVkeHUh?=
NCI-H838 M4Pvc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfZTWM2OD14Lkm2OFkh|ryP NFO1N4pUSU6JRWK=
NCI-H1299 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoD3TWM2OD14Lkm3NFkh|ryP MnjxV2FPT0WU
SW954 NXfrOpJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljyTWM2OD15LkKwNFY5KM7:TR?= MXjTRW5ITVJ?
NCI-H441 NGiy[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjrbnpWUUN3ME23MlM1ODZ3IN88US=> NEHsOXhUSU6JRWK=
SK-MEL-2 MoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTdwNEizO|Mh|ryP NH3iRmhUSU6JRWK=
KARPAS-45 M3r0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTzTWM2OD15Lk[1PVI6KM7:TR?= NFjFTGxUSU6JRWK=
CAL-54 NWTmWIM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjn[HhKSzVyPUeuPFI6PzdizszN M1fkOnNCVkeHUh?=
KYSE-180 NGPkVmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVX5PZRIUUN3ME23Mlg5QTRzIN88US=> NVLvclRtW0GQR1XS
NCI-H187 NX\UN21NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13rVGlEPTB;Nz65OVk1PyEQvF2= NX\KWoJDW0GQR1XS
RT-112 M13zdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYj0XHU3UUN3ME24MlA6Pjd5IN88US=> NUjP[|h4W0GQR1XS
NCI-H1437 M4j5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4frU2lEPTB;OD6wPVc6PSEQvF2= MUDTRW5ITVJ?
SNU-449 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRThwMkiyO|Ih|ryP M3v4PHNCVkeHUh?=
HCC1187 NUXtPHNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\wSmZKSzVyPUiuNlk{QTFizszN Ml62V2FPT0WU
NCI-H2030 MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnkSo02UUN3ME24MlM4PzF2IN88US=> NUTtSYJCW0GQR1XS
HuO-3N1 MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRThwM{e4OFQh|ryP MorCV2FPT0WU
COLO-792 Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLk[5JKSzVyPUiuOFE2OjdizszN Mkn3V2FPT0WU
MIA-PaCa-2 NWDEfJBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofaTWM2OD16Lki1OVA5KM7:TR?= MXHTRW5ITVJ?
SK-N-FI M{nMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkS0TWM2OD17LkC0NlUh|ryP NFKzbVZUSU6JRWK=
MMAC-SF NHXwcVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jifmlEPTB;OT6wPVc2OSEQvF2= M1Pmc3NCVkeHUh?=
NCI-H28 MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moe5TWM2OD17LkGwOFY6KM7:TR?= MUXTRW5ITVJ?
ETK-1 M3LnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nN[2lEPTB;OT6yPVk4PCEQvF2= NVnD[ZpCW0GQR1XS
NCI-H1993 NHHyZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTlwNESyOlEh|ryP MX7TRW5ITVJ?
no-11 NFewUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTlwNEexNkDPxE1? M4fGOnNCVkeHUh?=
ChaGo-K-1 M1WwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XuS2lEPTB;OT61NVU5OyEQvF2= NHezN4pUSU6JRWK=
NCCIT NH:zXFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHOU2hKSzVyPUmuOVMyPjlizszN M4XHRXNCVkeHUh?=
SAS M4fZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXNTWM2OD1zMD6yOFgh|ryP Mn7CV2FPT0WU
A673 NGLNOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFyLkO3NFQh|ryP M{TwdnNCVkeHUh?=
NCI-H1522 NIjad4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\sZ2lEPTB;MUCuN|cxPyEQvF2= M2HpPXNCVkeHUh?=
NCI-H810 NXjnepBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjOclVUUUN3ME2xNE4{QTB5IN88US=> M{jZU3NCVkeHUh?=
IST-MES1 M1HXc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXwNZdKSzVyPUGwMlQ2PjRizszN MoS2V2FPT0WU
GR-ST M2P6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nLeGlEPTB;MUCuOVAzPCEQvF2= NGPOfmFUSU6JRWK=
SUP-T1 NV3LOox2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrJd3l4UUN3ME2xNE44OzF5IN88US=> MoP5V2FPT0WU
NB5 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnmxTWM2OD1zMD65NFIzKM7:TR?= Mn6xV2FPT0WU
MZ1-PC MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkK1TWM2OD1zMD65OVcyKM7:TR?= NU\4PIpHW0GQR1XS
SK-CO-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjFOmxKSzVyPUGwMlk6OzFizszN MVnTRW5ITVJ?
Capan-2 NXLOd|R5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFzLkOxPVgh|ryP M1TkdXNCVkeHUh?=
697 MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TTR2lEPTB;MUGuOlc2PyEQvF2= MmPzV2FPT0WU
REH MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorWTWM2OD1zMT63OFUyKM7:TR?= MXHTRW5ITVJ?
GI-1 NFHEWG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlm2TWM2OD1zMT64OlE2KM7:TR?= NHnNVI5USU6JRWK=
BB65-RCC M{XDPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LsSWlEPTB;MUKuNFkyPiEQvF2= NHzsUnhUSU6JRWK=
NCI-H1651 M1j0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LHSmlEPTB;MUKuNlQ4QCEQvF2= M2X4NnNCVkeHUh?=
NCI-H1618 NVKxdVR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPjTWM2OD1zMj6zPVc3KM7:TR?= NGnDe|RUSU6JRWK=
NCI-H2081 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTF{Lk[xOFEh|ryP MXjTRW5ITVJ?
GCIY MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfkeXlKSzVyPUGyMlczOTNizszN MkO3V2FPT0WU
NY M{Px[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoewTWM2OD1zMz6wOlQ{KM7:TR?= NET6NYRUSU6JRWK=
PANC-03-27 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkX4TWM2OD1zMz6wPFA4KM7:TR?= NVK0UI5FW0GQR1XS
BHY NXXseXZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPyTWM2OD1zMz6yNVIyKM7:TR?= M4LpXXNCVkeHUh?=
SK-OV-3 Ml73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTF|LkO3OlMh|ryP M2DMbnNCVkeHUh?=
5637 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTF|Lke3OVkh|ryP M3PlSHNCVkeHUh?=
LC-1F MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvjV2hGUUN3ME2xOE4xOzV4IN88US=> NEjtW3hUSU6JRWK=
SNB75 NF3KNXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\iZnVKUUN3ME2xOE4xOzh|IN88US=> Mle3V2FPT0WU
CHP-212 NXPWVFl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoWyTWM2OD1zND6wOFY1KM7:TR?= MkLSV2FPT0WU
HT-1376 MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTF2LkGxNlYh|ryP NXOyXWhJW0GQR1XS
MONO-MAC-6 NFzSXo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTF2LkG1NFIh|ryP NETQTIlUSU6JRWK=
CA46 M2Wwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrXTWM2OD1zND6xPFI4KM7:TR?= NELyTotUSU6JRWK=
SCC-15 NGHZeZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[zV2hjUUN3ME2xOE42PTh|IN88US=> MUnTRW5ITVJ?
ATN-1 MkmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHnTWM2OD1zND62OlI4KM7:TR?= NXXDR4hDW0GQR1XS
NCI-H2405 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF2LkixOVch|ryP NIi5TnNUSU6JRWK=
NCI-H716 MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT6VotxUUN3ME2xOE45PDl|IN88US=> MUDTRW5ITVJ?
SW620 M2Pre2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjwRVhKSzVyPUG0MlkxOTRizszN NH\BWnRUSU6JRWK=
NCI-H226 MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPCTWM2OD1zND65NFg2KM7:TR?= NYLFOm56W0GQR1XS
SW962 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF2Lkm0N|Ih|ryP MnLzV2FPT0WU
KYSE-150 MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTF2Lkm1OUDPxE1? MUTTRW5ITVJ?
OCUB-M NEW2dIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjueXh1UUN3ME2xOE46QDh|IN88US=> MYfTRW5ITVJ?
ES7 M2fVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;pTWM2OD1zNT6wPVg1KM7:TR?= NHXoXWlUSU6JRWK=
SW1463 M3jKfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvZSINKSzVyPUG1MlQzOjNizszN MWHTRW5ITVJ?
CAKI-1 M{X5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF3LkWzOFYh|ryP NGHMdnpUSU6JRWK=
MKN28 NV7wVmFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f0ZWlEPTB;MUWuOVQ4QSEQvF2= NXjOWpRoW0GQR1XS
SW13 NX:0dW1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTF3Lk[xPEDPxE1? NYHJUlRvW0GQR1XS
A3-KAW NHHSRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PYXmlEPTB;MUWuPVY6PyEQvF2= MULTRW5ITVJ?
LU-65 NU[yUGpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{e0V2lEPTB;MUWuPVc3QCEQvF2= NUDyOm1LW0GQR1XS
Calu-1 M{nGfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPCW3RKSzVyPUG2MlA{PjhizszN M3m0cnNCVkeHUh?=
ST486 NYjofG9TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF4LkC0N|Eh|ryP NVLQZmpSW0GQR1XS
BB30-HNC M33QfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrXTWM2OD1zNj6xNlQ3KM7:TR?= M1rkU3NCVkeHUh?=
EGI-1 NF3tepBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF4LkS0OkDPxE1? NFHSSYxUSU6JRWK=
SH-4 NXrHUo5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrlTWM2OD1zNj60O|MyKM7:TR?= M4H3fXNCVkeHUh?=
MN-60 MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTDTWM2OD1zNz6yNlk4KM7:TR?= NG[3[FBUSU6JRWK=
MPP-89 MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnO0TWM2OD1zNz6yOFU6KM7:TR?= NVzKeG53W0GQR1XS
A2780 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nqRWlEPTB;MUeuOFE{QSEQvF2= NESzSJRUSU6JRWK=
Daoy NHXy[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\oN5hsUUN3ME2xO{41Pjl3IN88US=> NYHoeW9YW0GQR1XS
NCI-H2126 M1jObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nOT2lEPTB;MUeuOFc4OSEQvF2= NHi1SHRUSU6JRWK=
NCI-H1563 NIOyUYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfiXGw5UUN3ME2xO{41QTF5IN88US=> NEOxc4xUSU6JRWK=
8-MG-BA NYm5UVNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\GXHRKSzVyPUG3MlY3PDhizszN MXfTRW5ITVJ?
786-0 M3\Yd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvwTWM2OD1zNz64N|U{KM7:TR?= M3n1[nNCVkeHUh?=
AM-38 M3m5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\CVmxKSzVyPUG3Mlk{ODZizszN NGjNZVVUSU6JRWK=
COLO-824 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF6LkS0N|Yh|ryP MWnTRW5ITVJ?
SK-MEL-30 NF;LVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2q3SWlEPTB;MUiuOVA5OiEQvF2= NIjCU3JUSU6JRWK=
CESS M4ToN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILzSWRKSzVyPUG4Mlc3ODlizszN MWnTRW5ITVJ?
BL-70 NFTJZWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLFTWM2OD1zOD64NVU3KM7:TR?= M1;iNXNCVkeHUh?=
NCI-H2170 NELaT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXoc3JOUUN3ME2xPE46OTd7IN88US=> NXvFU|JxW0GQR1XS
HT-3 MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3uTWM2OD1zOD65PFMh|ryP M4OwNHNCVkeHUh?=
BOKU NHq2TolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXQTWM2OD1zOT6wN|gyKM7:TR?= NV2yNIpuW0GQR1XS
HPAF-II NYDHd3RbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTF7LkOwNVUh|ryP NITUb|VUSU6JRWK=
KGN NUPGS4tOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4K2R2lEPTB;MUmuOFc3PSEQvF2= MUPTRW5ITVJ?
MC-CAR NW\jb5poT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jCfGlEPTB;MUmuOlMyOyEQvF2= NWrGU2JYW0GQR1XS
BHT-101 NXnzd|dST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3QN|RKSzVyPUG5Mlc4PyEQvF2= M{PVe3NCVkeHUh?=
SW1783 NFG3Z|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nDO2lEPTB;MUmuO|gxPiEQvF2= MoP0V2FPT0WU
KP-N-YN NInYPVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DiRmlEPTB;MkCuNFI3OiEQvF2= NFfhXHZUSU6JRWK=
LU-165 M1TlPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHwTWM2OD1{MD61OVcyKM7:TR?= NUTBbldzW0GQR1XS
GOTO NVLKfXpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGriWHZKSzVyPUKwMlY1PTFizszN MVPTRW5ITVJ?
EFM-19 MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJzLkC3NVYh|ryP NHGwbnBUSU6JRWK=
CTV-1 M3jq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e4WmlEPTB;MkGuNVA2PCEQvF2= MlO2V2FPT0WU
HEL MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJzLkSyNVYh|ryP NIrlXZpUSU6JRWK=
SNU-C2B MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLWeZBMUUN3ME2yNU41OjZizszN NUPKWHhEW0GQR1XS
ECC4 NUDsUVlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ixemlEPTB;MkGuO|A4KM7:TR?= MoPNV2FPT0WU
NEC8 NI\aWYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\wTWM2OD1{MT64N|Y5KM7:TR?= MoLNV2FPT0WU
KMOE-2 NUfUSYpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XTdGlEPTB;MkGuPFkzOSEQvF2= MmLJV2FPT0WU
NCI-H524 M{TJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJ{LkC4NFgh|ryP NWPLeHRKW0GQR1XS
WSU-NHL MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTJ{LkG1O|ch|ryP NUDuclJ{W0GQR1XS
SF126 MkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGmyUI1KSzVyPUKyMlI1PjlizszN M4TyRnNCVkeHUh?=
HOP-92 M{LDb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;rTWM2OD1{Mj6zNVY4KM7:TR?= NEOzSGlUSU6JRWK=
CTB-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTJ{LkS2O|ch|ryP NX34UGt{W0GQR1XS
KYSE-270 M1jkSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\yTohKSzVyPUKyMlk{PTdizszN M3XGZnNCVkeHUh?=
SK-MEL-24 M2PiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLITWM2OD1{Mz6xPFch|ryP M3:xW3NCVkeHUh?=
Calu-3 M4\Scmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfJTWM2OD1{Mz6yNVI5KM7:TR?= MmDYV2FPT0WU
GAMG NEXJeFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\tTWM2OD1{Mz6yN|Y4KM7:TR?= MmfrV2FPT0WU
SW1573 NIPwUVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LaPGlEPTB;MkOuO|QyPSEQvF2= NIj5VmdUSU6JRWK=
MHH-NB-11 NUjBb3IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHKbIdKSzVyPUK0MlAyQTRizszN NE\YOFZUSU6JRWK=
TK10 M4HqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmmzTWM2OD1{ND61NFE{KM7:TR?= M4\ON3NCVkeHUh?=
LB373-MEL-D NW\LVog2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlW0TWM2OD1{ND62NFY1KM7:TR?= NFmxdIdUSU6JRWK=
KALS-1 MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFP4fnJKSzVyPUK0Mlc{OjdizszN MnfxV2FPT0WU
HUTU-80 NWXSdWF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrTdVlmUUN3ME2yOU45ODN{IN88US=> M1j1bXNCVkeHUh?=
HuP-T3 NHHPe5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;CXWNyUUN3ME2yOk4yPjd2IN88US=> NEjFbmZUSU6JRWK=
OE19 NVy2PVlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfVTWM2OD1{Nj6yNVU{KM7:TR?= M2TkRXNCVkeHUh?=
J82 MmPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTCS4lzUUN3ME2yOk4zPDdzIN88US=> NEHNSXRUSU6JRWK=
DU-4475 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJ4LkO4NVkh|ryP NH6zOFNUSU6JRWK=
DMS-53 NXXNVXNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvNZlRKSzVyPUK2MlUyOzhizszN M4WxSHNCVkeHUh?=
COLO-741 NF7ESZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPDNXV2UUN3ME2yOk45OzR2IN88US=> NYXmT21PW0GQR1XS
SW48 M3z0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HtNGlEPTB;Mk[uPFgzKM7:TR?= M3\yVHNCVkeHUh?=
IGR-1 NE\pNIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlruTWM2OD1{Nj65N|M1KM7:TR?= M{TQWHNCVkeHUh?=
639-V NIjEOJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXq3Uo5GUUN3ME2yO{4xOjR3IN88US=> M1G1NXNCVkeHUh?=
LK-2 NHz5RWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIL5cYFKSzVyPUK3MlQyPDFizszN MnHYV2FPT0WU
NCI-H2347 NFrtVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jDVWlEPTB;MkeuPVY6QSEQvF2= M{LwSnNCVkeHUh?=
NCI-H2228 NIXJV2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\NTWM2OD1{OD6wPVA2KM7:TR?= M4TxSXNCVkeHUh?=
LS-123 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJ6LkGyOlIh|ryP NV;RbXJUW0GQR1XS
U031 NW\vb|k{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTJ6LkK1NkDPxE1? NV;RfYR6W0GQR1XS
NCI-H1792 MkHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DPNWlEPTB;MkiuOFczOSEQvF2= NWS0NGFDW0GQR1XS
NCI-H2087 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL0TWM2OD1{OD63OVUzKM7:TR?= NWfIXW9LW0GQR1XS
NCI-H2342 Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ7LkWyNFgh|ryP MmLsV2FPT0WU
SW626 M{m2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJ7Lke1OkDPxE1? NEf2b41USU6JRWK=
LB2518-MEL NE\ZN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO4PWN4UUN3ME2yPU45OTVizszN MWHTRW5ITVJ?
RXF393 MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTNyLkC5OVIh|ryP MmG2V2FPT0WU
LC4-1 M4HMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXqe3BKSzVyPUOwMlMxQTJizszN M3O1SXNCVkeHUh?=
NCI-H1694 M2H3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTNyLk[2NlQh|ryP NVW4NYY4W0GQR1XS
K5 NHGwUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXlTWM2OD1|MD65O|AzKM7:TR?= NFrEVJZUSU6JRWK=
HDLM-2 M2[5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlq4TWM2OD1|MD65O|I2KM7:TR?= NEjJSHVUSU6JRWK=
BCPAP NV3velhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTNzLkizO|kh|ryP MWjTRW5ITVJ?
BC-3 NXi2NXNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3uTWM2OD1|Mj6xOFA{KM7:TR?= M17IZXNCVkeHUh?=
LB996-RCC NIDxS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV33VGVzUUN3ME2zNk4zOzV6IN88US=> M2fPbXNCVkeHUh?=
NCI-H2009 MoDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Xa[2lEPTB;M{KuOFk5OSEQvF2= NHy4U3VUSU6JRWK=
HTC-C3 NGDL[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fOXmlEPTB;M{OuO|UyQSEQvF2= M4HtOXNCVkeHUh?=
LAMA-84 MknLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHDc|ViUUN3ME2zOE41PDB5IN88US=> NIHjN3hUSU6JRWK=
CCRF-CEM M2C3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlixTWM2OD1|ND61O|E2KM7:TR?= M2fi[nNCVkeHUh?=
AN3-CA M3\jVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\sb|lKSzVyPUO1MlA2PjhizszN MUnTRW5ITVJ?
NCI-H1734 NHHX[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XEXWlEPTB;M{WuNlU3OSEQvF2= MW\TRW5ITVJ?
Ca-Ski MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIW1[4pKSzVyPUO1MlQyODFizszN MYjTRW5ITVJ?
U-266 MlTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrETWM2OD1|NT62NVE1KM7:TR?= M4\kc3NCVkeHUh?=
SBC-5 MlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzRTWM2OD1|NT63O|gyKM7:TR?= MXfTRW5ITVJ?
GT3TKB NFX4OnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUW1OnlLUUN3ME2zO{4yOTVizszN NE\Ge|JUSU6JRWK=
MDA-MB-175-VII Ml\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXBV2tKSzVyPUO3MlIzPDhizszN MlHqV2FPT0WU
PFSK-1 M4TnfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfLRWl2UUN3ME2zO{4zPDN3IN88US=> MXPTRW5ITVJ?
IMR-5 NVu0XYtPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zjWGlEPTB;M{euNlQ5PyEQvF2= NX3ZXohLW0GQR1XS
Daudi MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTN5LkO1PVch|ryP MX\TRW5ITVJ?
A498 NF2zW4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;WZm1{UUN3ME2zO{44OjF6IN88US=> NYjmeGlLW0GQR1XS
SCC-4 M{XuV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTUTJc4UUN3ME2zO{44QDR|IN88US=> NVjvT|hSW0GQR1XS
COLO-680N NWfqfJpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDLd5JKSzVyPUO4MlI5QDVizszN MlHUV2FPT0WU
SK-MES-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnXWXdiUUN3ME2zPE4{OjF3IN88US=> NUXvV2xbW0GQR1XS
SR MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTN6LkW0PVUh|ryP M4\WXnNCVkeHUh?=
LNCaP-Clone-FGC Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmixTWM2OD1|OD61OlM4KM7:TR?= NXnER2xmW0GQR1XS
SK-HEP-1 NYXNNW4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXiXW5KSzVyPUO4Mlc5OjJizszN M1f4OnNCVkeHUh?=
BPH-1 M4\OO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknlTWM2OD1|OD64N|I6KM7:TR?= NWji[o9ZW0GQR1XS
NCI-H1755 NV62bnFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFW1V5VKSzVyPUO5MlU5OTdizszN M3zX[XNCVkeHUh?=
LXF-289 NGP1Z2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTN7LkiwPFQh|ryP Ml\yV2FPT0WU
SW1088 Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP4TWM2OD12MD6yNVA4KM7:TR?= M{XzO3NCVkeHUh?=
MOLT-4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHv4UmFKSzVyPUSwMlI6ODFizszN MmnDV2FPT0WU
AsPC-1 M1HqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXwTWM2OD12MD60OVg{KM7:TR?= MkntV2FPT0WU
HOP-62 NUmyPFd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojPTWM2OD12MD62OVY5KM7:TR?= MX7TRW5ITVJ?
A172 NHu2U29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnUZpRKSzVyPUSwMlg2OTFizszN NGrJVFNUSU6JRWK=
SN12C MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rFS2lEPTB;NECuPVM5PSEQvF2= NYLwV5hxW0GQR1XS
MDA-MB-231 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlv3TWM2OD12MD65PFk5KM7:TR?= M2TIb3NCVkeHUh?=
RPMI-2650 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTRzLkG1PVMh|ryP NFjKeoFUSU6JRWK=
KYSE-140 MkPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTRzLkixNlMh|ryP M3rQNXNCVkeHUh?=
KINGS-1 MoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzNU4J2UUN3ME20Nk41Pjl5IN88US=> MYfTRW5ITVJ?
HSC-3 NFfuelFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHW5d|VKSzVyPUSyMlY3PjFizszN MUjTRW5ITVJ?
PC-14 MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrZTWM2OD12Mz6xPFgzKM7:TR?= M4TmbHNCVkeHUh?=
COR-L105 NEXnWG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rCdWlEPTB;NEOuOlUxOiEQvF2= NF3iOYNUSU6JRWK=
BE-13 NYHhdXZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTR2LkKzO|Eh|ryP M4Hv[3NCVkeHUh?=
NCI-H661 Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTR2LkK5OVgh|ryP MVrTRW5ITVJ?
IST-MEL1 MnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PhOGlEPTB;NESuN|U6QSEQvF2= NGXWNWxUSU6JRWK=
HCC1806 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3rTWM2OD12ND61PFc{KM7:TR?= MVfTRW5ITVJ?
COLO-800 Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrzdnJKSzVyPUS0Mlg1PTNizszN MlrSV2FPT0WU
IST-SL2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PYcmlEPTB;NEWuNVI1PyEQvF2= MXzTRW5ITVJ?
8305C MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrXdGNiUUN3ME20OU4{ODlizszN NFXlO3VUSU6JRWK=
UACC-62 NXn2RXp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XNbmlEPTB;NE[uNlg4PSEQvF2= NVTzcmhiW0GQR1XS
COR-L23 MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7yTWM2OD12Nz6xPVkh|ryP NW[z[VlXW0GQR1XS
EFE-184 M{XvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\GR2hYUUN3ME20O{4{QDhizszN MYPTRW5ITVJ?
DMS-114 NXnBUWhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXtTWM2OD12Nz60NVQ6KM7:TR?= NGXTfYJUSU6JRWK=
KYSE-520 NYK3[XN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG1c21KSzVyPUS4MlU{OTVizszN MkfFV2FPT0WU
SNG-M NV3ROGJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWezZYFGUUN3ME20PU41OzRizszN NWH1eXBqW0GQR1XS
A2058 NIfpWmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTYRlVKSzVyPUS5MlQ5QDVizszN MoG4V2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo試験 OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]
臨床試験 OSI-906 is currently under a Phase III clinical trial in adrenocortical carcinoma (ACC).
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

Protein kinase biochemical assays Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.

細胞アッセイ: [1]

細胞株 MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
濃度 0.02-0.8 μM
反応時間 3 days
実験の流れ For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.

動物実験: [1]

動物モデル IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
製剤 25 mM tartaric acid
投薬量 25 mg / kg and 75 mg / kg
投与方法 Orally administrated at once-daily oral dose for 14 days

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download OSI-906 (Linsitinib) SDF
分子量 421.49
化学式

C26H23N5O

CAS No. 867160-71-2
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 84 mg/mL (199.29 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 30% PEG 400+0.5% Tween 80+5% Propylene glycol 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol

カスタマーフィードバック (3)


Click to enlarge
Rating
Source Cancer Res, 2013, 73, 834-843. OSI-906 (Linsitinib) purchased from Selleck
Method Cell proliferation and growth assays
Cell Lines PFR3 cells
Concentrations 1 μM
Incubation Time
Results The IC50 of PFR3 cells for PF299804 was more than 100 fold lower with the combination of OSI-90 than with PF00299804 alone.

Click to enlarge
Rating
Source Cancer Res, 2011, 71, 6773-84. OSI-906 (Linsitinib) purchased from Selleck
Method [18 F]FDG –PET/ Western blot
Cell Lines MCF-7 cells/athymic mice
Concentrations 50 mg/kg/day
Incubation Time 6 weeks
Results mice without palpable tumors were randomized to treatment with vehicle or OSI-906. Six of 20 control mice (30%) developed tumors, whereas none of the 20 OSI-906–treated mice did (Fig. A). OSI-906 inhibited tumor growth compared with vehicle (Fig. B; P < 0.05). OSI-906–treated tumors exhibited markedly lower levels of phosphorylated IGF-IR, InsR, IRS-1, AKT, and S6 compared with vehicle controls (Fig. C). FDG uptake was significantly decreased 4 hours after a single dose of OSI-906 com-pared with baseline (Fig. D)

Click to enlarge
Rating
Source OSI-906 (Linsitinib) purchased from Selleck
Method Flow cytometry/ Western Blotting
Cell Lines CLL B cells
Concentrations 1 µM
Incubation Time 24 h
Results three structurally unrelated IGF1R inhibi tors AG1024, Picropodophyllin (PPP) and linsitinib significantly reduced the cellular viability of primary CLL cells ( Figure A) and reduced levels of phosphorylated IGF1R and IRS-1 (Figure B,C). AG1024, which showed the strongest effect on viability, caused a dose-dependent decrease in the levels of phosphorylated Src, PI3K, Akt, MEK and ERK (Figure D).

文献中の引用 (15)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related IGF-1R 阻害剤

  • Picropodophyllin (PPP)

    Picropodophyllin (PPP) is a selective IGF-1R inhibitor with IC50 of 1 nM. Phase 1/2.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • Pexidartinib (PLX3397)

    Pexidartinib (PLX3397) is an oral, potent mutil-targeted receptor tyrosine kinase inhibitor of CSF-1R, Kit, and Flt3 with IC50 of 20 nM, 10 nM and 160 nM, respectively. Phase 3.

  • BMS-536924

    BMS-536924は、ATP競争的IGF-IRとIR阻害剤で、IC50 がそれぞれ 100 nM と 73 nMです。

  • NVP-AEW541

    NVP-AEW541は、IGF-IRとInsRの二重阻害剤で、IC50 がそれぞれ 86 nM と 140 nMです。

  • NVP-ADW742

    NVP-ADW742は、0.17のμMのIC50によるIGF1R阻害剤です。

  • GSK1904529A

    GSK1904529Aは選択性阻害剤、(IGF-IR) と (IR)を抑制する時、 IC50が それぞれ27 nM と 25 nMになる.

  • BMS-754807

    BMS-754807は、IGF1R/IR家族キナーゼの強力で可逆的な阻害剤で、 IGF-1RIRMetTrkATrkBを妨げ、IC50 がそれぞれ 1.8 nM、1.7 nM、5.6 nM、7.4 nM 、 4.1 nMです。

    Features:Muti-inhibitor of the IGR-1R/IR family.

最近チェックしたアイテム

Tags: OSI-906 (Linsitinib)を買う | OSI-906 (Linsitinib)供給者 | OSI-906 (Linsitinib)を購入する | OSI-906 (Linsitinib)費用 | OSI-906 (Linsitinib)生産者 | オーダーOSI-906 (Linsitinib) | OSI-906 (Linsitinib)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ